AIP
ELEV

Ameritas Investment Partners’s Elevation Oncology ELEV Stock Holding History

Ameritas Investment Partners’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,111
Closed -$1.32K – 3243
2025
Q1 		$1.32K Hold
5,111
– – ﹤0.01% 3092
2024
Q4 		$2.88K Hold
5,111
– – ﹤0.01% 3081
2024
Q3 		$3.07K Hold
5,111
– – ﹤0.01% 3080
2024
Q2 		$13.8K Buy
+5,111
New +$19.2K ﹤0.01% 2794

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Ameritas Investment Partners's ELEV Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 5,111 shares — an estimated $1.32K sold.

Ameritas Investment Partners first reported a position in ELEV in Q2 2024 and held it in 4 quarters. The position peaked at $13.8K in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 5,111 Elevation Oncology shares in Q2 2025, an estimated $1.32K.
  • Ameritas Investment Partners first reported a position in Elevation Oncology in Q2 2024 and held it in 4 quarters.
  • Ameritas Investment Partners's Elevation Oncology position peaked at $13.8K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.